Novel therapeutics to conquer cancer:

Speeding smarter therapies to patients

UChicago researchers are advancing cancer treatment with new therapies that work with the body’s healthy systems instead of against them, that leave patients stronger instead of weaker, that destroy cancer and guard against its potential return.

Made in UChicago

A complete pipeline for new drug discovery―from basic research to chemical synthesis, to designing delivery mechanisms, to preclinical testing, to clinical research―exists within the University of Chicago.
We are putting our deep scientific bench strength to work on producing new cellular therapies, advancing theranostics―a one-two punch against cancer―that simultaneously seeks out and destroys cancer cells without damaging nearby tissue, and pursuing new ways to bolster survivorship, such as preventing cachexia, the life-threatening wasting syndrome that many cancer patients develop.

A one-and-only scientific ecosystem

UChicago encompasses large-scale research enterprises engaged in cancer-relevant research. Each offers specialized skills and technologies not available elsewhere, allowing faster pursuit of deeper, more complex questions.

The Argonne National Laboratory >
The Duchossois Family Institute >
The Pritzker School for Molecular Engineering >
The Polsky Center for Entrepreneurship and Innovation >
Our Comprehensive Cancer Center faculty offer clinical trials at twice the rate of their peers at other nationally recognized cancer
Masked cancer drug reduces side-effects
Did you know? Developing a new drug can take 10-15 years, from lab to patient, and require review of a quintillion (a billion billions) compounds.
Our Comprehensive Cancer Center faculty offer clinical trials at twice the rate of their peers at other nationally recognized cancer
Masked cancer drug reduces side-effects
Did you know? Developing a new drug can take 10-15 years, from lab to patient, and require review of a quintillion (a billion billions) compounds.
Our Comprehensive Cancer Center faculty offer clinical trials at twice the rate of their peers at other nationally recognized cancer centers.

NOVEL THERAPY

Mask cancer drug reduces side-effects

New immunotherapy would activate on contact with tumors.
Scroll to Top
Skip to content